Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
PaxMedica, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on PaxMedica, Inc.|
Txns:
| Paid exercise price by delivering 6,536 shares
@ $0.2861, valued at
$1.9k
|
|
| 09/27/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/23/2023 |
4
| Rome Zachary (Director) has filed a Form 4 on PaxMedica, Inc.|
Txns:
| Sold 20,000 shares
@ $0.5813, valued at
$11.6k
Sold 30,000 shares
@ $0.5412, valued at
$16.2k
|
|
| 08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/17/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/16/2023 |
3
| Hough David W. (Chief Medical Officer) has filed a Form 3 on PaxMedica, Inc. |
| 08/16/2023 |
8-K
| Resignation/termination of a director |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results|
Docs:
|
"PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update TARRYTOWN, NY, August 9, 2023– PaxMedica, Inc. , a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the second quarter 2023, ended June 30, 2023. Recent Highlights · Announced positive top line results from the PAX-101 Phase 3 African Sleeping Sickness Study, PAX-HAT-301, paving the way for an expected NDA filing in 2024 · Granted Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with autism ..." |
|
| 08/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 06/16/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results|
Docs:
|
"PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023 Tarrytown, N.Y. May 15, 2023 - PaxMedica, Inc. , a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the first quarter 2023 ended March 31, 2023. Howard Weisman, Chief Executive Officer of PaxMedica, commented, “During the first quarter we’ ve continued working hard to advance the ongoing retrospective Phase 3 HAT-301 trial and we continue to expect to announce top line results in the second half of 2023. The study, if successful, is expected to lead to the submission of a New..." |
|
| 05/12/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/11/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/01/2023 |
4/A
| Rome Zachary (COO) has filed a Form 4 on PaxMedica, Inc.|
Txns:
| Paid exercise price by delivering 9,584 shares
@ $1.61, valued at
$15.4k
|
|
| 05/01/2023 |
4/A
| LaRochelle Karen (Director) has filed a Form 4 on PaxMedica, Inc.|
Txns:
| Paid exercise price by delivering 1,143 shares
@ $1.61, valued at
$1.8k
|
|
| 04/24/2023 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|